Patient-derived induced pluripotent stem cells (iPS cells) are quickly becoming a promising new approach for modeling human diseases in a culture dish. This is especially true for neurodegenerative diseases, including ALS. Recently, researchers from Kyoto University generated nine iPS cell lines from three different people with ALS. The researchers were able to differentiate the iPS cells into neurons that they used to screen drugs that could reverse some of the ALS-related toxicity, a technique that has significant amount of promise for identifying potential drug candidates for neurodegenerative diseases. EMD Millipore recently licensed this technology from iPS Academia Japan Inc. (AJ), which is an affiliate of Kyoto University. Maybe EMD Millipore has plans to use this technology to identify potential ALS therapeutics?
Click here to read more.Share this: